ESPE2015 Poster Category 2 Diabetes (60 abstracts)
Recombinant Human IGF1 Treatment in Patients with Insulin Receptor Mutations Resulting in Donohue Syndrome: A 10-Year Experience in a Tertiary Centre
Nicola Improda a , Harshini Katugampola a , Pratik Shah a, , Hannah Gordon a , Rakesh Amin a, , Catherine J Peters a, , Robert K Semple c & Mehul T Dattani a,
aLondon Centre for Paediatric Endocrinology, Great Ormond Street Hospital for Children NHS Trust, London, UK; bInstitute of Child Health, London, UK; cDepartment of Clinical Biochemistry, University of Cambridge, Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, UK
Background: Donohue syndrome (DS) is the most severe form of insulin-resistance due to autosomal recessive mutations in the insulin receptor gene. Previous reports demonstrate a role for recombinant human IGF1 (rhIGF1), however optimal treatment strategy remains unclear.
Case series: Four males with DS have been treated with bolus rhIGF1 (see table below). They had no IGF1 response on an IGF1 generation test. No long-term side effects of rhIGF1 were reported.
Conclusion: High dose rhIGF1 is safe and can mitigate metabolic abnormalities in patients with DS. We report survival into adolescence in a patient with no severe comorbidities, in whom the fast tolerance dramatically improved on rhIGF1 and long-term growth was relatively preserved. Although a twice daily regimen is the most frequently reported, 8 h administration may be required to optimise metabolic control, as demonstrated in Patient 2.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more